Detecting Neonatal Hypoglycemia Using Real-Time Continuous Glucose

Status Completed

Clinical Trial Summary

Hypoglycemia is the most common metabolic problem faced after birth. The investigators will be studying the utility of using a continuous glucose monitoring(CGM) system to more closely monitor low blood sugars in newborns. The investigators will evaluate the number of hypoglycemic events detected using CGM and compare it to those detected using current standard of care screening methods.

Clinical Trial Description

A CGM will be subcutaneously inserted by trained staff on a healthy area of skin and will be calibrated according to the manufacturer's instructions. Blood glucose measurements will be taken using a blinded study glucometer to calibrate the device. Calibration by trained study staff will take place about every 12 hours. Sensor insertion sites will be monitored for infection throughout the course of the study by nursing and clinical staff or by trained study staff on an as needed basis. At the conclusion of the study, the CGM will be removed and assessed for signs of infection. Study duration will be up to 7 days while the patient is admitted to the hospital.

Participants will be randomized into 2 groups. The control group will have a blinded CGM in place for the duration of the study. The remote monitoring group will be blinded to clinical staff. This group will have a CGM connected to an iPod that sends continuous glucose data to the study phone and will be monitored 24/7 by study staff. If a blood sugar level of <46 mg/dl is detected, the infant will first be evaluated for positioning that could be causing a falsely low value. If the infant is re-positioned and CGM continues to show a blood sugar level of <46 mg/dl, study staff will prompt the nurse taking care of the patient to obtain a capillary glucose value to verify the low blood sugar and treat it as deemed appropriate by the clinical team.

The investigators will evaluate the number of hypoglycemic events that occur in the blinded CGM group versus the number that occur in the remote monitoring group to assess if the CGM is able to more sensitively detect low blood sugars in infants than current hospital standard of care measures. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03032523
Study type	Interventional
Source	Stanford University
Contact
Status	Completed
Phase	N/A
Start date	October 1, 2016
Completion date	April 1, 2018

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02583776` - Continuous Glucose Monitoring and Preterm Infants	Phase 4
Not yet recruiting	`NCT05977972` - Pattern of Metabolic Causes of Neonatal Hypoglycemia
Recruiting	`NCT04458649` - Continuous Glucose Monitoring in Infants
Recruiting	`NCT05127070` - Evaluating the NeoTree in Malawi and Zimbabwe
Completed	`NCT03726697` - Effect of Tahneek on Hypoglycemia in Newborn Infants	N/A
Terminated	`NCT04085978` - Effects of a Hypoglycemia Protocol With Glucose Gel on Neonatal Intensive Care Unit (NICU) Admission
Recruiting	`NCT05647798` - Intrapartum Glycemic Control in GDMA2	N/A
Not yet recruiting	`NCT04811612` - Comparing Heel Stick Glucoses in Neonates	N/A
Not yet recruiting	`NCT02648555` - A Lifestyle Intervention to Improve in Vitro Fertilization Results	N/A
Completed	`NCT04030312` - Effectiveness of Donor Human Milk Supplementation for the Treatment of Hypoglycemia in the Breastfed Infant	N/A
Completed	`NCT03076775` - Euglycemia After Antenatal Late Preterm Steroids, the E-ALPS Study	N/A
Completed	`NCT05022433` - Comparison of the Shukla and UN-1 Formulae in the Placement of the Umbilical Venous Catheter Among Neonates
Recruiting	`NCT00332449` - Early Breast Feeding and Glucose Levels in High Risk Newborns	N/A
Not yet recruiting	`NCT04869709` - Late Preterm Corticosteroids and Neonatal Hypoglycemia	Phase 4
Completed	`NCT02523222` - Prophylactic Dextrose Gel for Newborns at High-risk for Hypoglycemia	N/A
Recruiting	`NCT04875624` - Neurodevelopment of Hypoglycemic Neonates
Completed	`NCT02605369` - SURVIVAL PLUSS: Increasing Capacity for Mama-baby Survival in Post-conflict Uganda and South Sudan	N/A
Withdrawn	`NCT03738293` - Continuous Glucose Monitoring of Late Preterm Birth After Corticosteroids
Recruiting	`NCT04386005` - Continuous Glucose Monitoring in At-Risk Newborns	N/A
Not yet recruiting	`NCT02838875` - To Examine if the Mother's Glucose Levels and Glucose Levels in the Blood Can Predict Cord Hypoglycemia in Newborns at Risk.	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Detecting Neonatal Hypoglycemia Using Real-Time Continuous Glucose Monitoring (CGM)

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms